MedTrace Logo

A SHR-1210 BE Study on Healthy Subjects

NCT05799183 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-12-31

No results posted yet for this study

Summary

The purpose of this study is to assess the bioequivalence of SHR-1210 before and after process changes.

Conditions

  • Advanced Tumors

Interventions

DRUG

SHR-1210

Subjects will receive treatment SHR-1210 before process changes 20 mg

DRUG

SHR-1210

Subjects will receive treatment SHR-1210 after process changes 20 mg

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-04
Primary Completion
2023-10-12
Completion
2023-10-12

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05799183 on ClinicalTrials.gov